IN2012DE00912A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00912A
IN2012DE00912A IN912DE2012A IN2012DE00912A IN 2012DE00912 A IN2012DE00912 A IN 2012DE00912A IN 912DE2012 A IN912DE2012 A IN 912DE2012A IN 2012DE00912 A IN2012DE00912 A IN 2012DE00912A
Authority
IN
India
Prior art keywords
stable
antioxidants
free
amino acids
chelating agents
Prior art date
Application number
Other languages
English (en)
Inventor
Dhiraj Khattar
Rajesh Khanna
Mukti Yuadav
Krishanu Burman
Original Assignee
Fresenius Kabi Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Oncology Ltd filed Critical Fresenius Kabi Oncology Ltd
Priority to PCT/IB2013/052356 priority Critical patent/WO2013144814A1/en
Priority to US14/387,670 priority patent/US20150073000A1/en
Priority to IN912DE2012 priority patent/IN2012DE00912A/en
Publication of IN2012DE00912A publication Critical patent/IN2012DE00912A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN912DE2012 2012-03-27 2013-03-25 IN2012DE00912A (enExample)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/IB2013/052356 WO2013144814A1 (en) 2012-03-27 2013-03-25 Stable ready-to-use pharmaceutical composition of pemetrexed
US14/387,670 US20150073000A1 (en) 2012-03-27 2013-03-25 Stable ready-to-use pharmaceutical composition of pemetrexed
IN912DE2012 IN2012DE00912A (enExample) 2012-03-27 2013-03-25

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN912DE2012 IN2012DE00912A (enExample) 2012-03-27 2013-03-25

Publications (1)

Publication Number Publication Date
IN2012DE00912A true IN2012DE00912A (enExample) 2015-09-11

Family

ID=48095972

Family Applications (1)

Application Number Title Priority Date Filing Date
IN912DE2012 IN2012DE00912A (enExample) 2012-03-27 2013-03-25

Country Status (3)

Country Link
US (1) US20150073000A1 (enExample)
IN (1) IN2012DE00912A (enExample)
WO (1) WO2013144814A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501773A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 用于口服给予的他喷他多含水药物制剂
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
HUE048357T2 (hu) 2014-10-16 2020-08-28 Synthon Bv Pemetrexedet tartalmazó folyékony gyógyszerészeti kompozíció
ES2928018T3 (es) * 2015-02-13 2022-11-15 Sun Pharmaceutical Ind Ltd Forma de dosificación para infusión intravenosa
US20170340639A1 (en) * 2015-03-26 2017-11-30 Ftf Pharma Private Limited Pharmaceutical composition of pemetrexed
ES2710299T3 (es) 2015-03-27 2019-04-24 Gruenenthal Gmbh Formulación estable para la administración parenteral de tapentadol
CA2994167A1 (en) * 2015-07-30 2017-02-02 Expression Pathology, Inc. Quantifying fr-a and gart proteins for optimal cancer therapy
AU2016393213B2 (en) * 2016-02-19 2022-03-31 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
JP6957233B2 (ja) * 2016-06-27 2021-11-02 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． ペメトレキセドの安定な注射溶液
ES3027562T3 (en) 2016-09-23 2025-06-16 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
EP3470045B1 (en) 2017-10-10 2020-09-02 Sun Pharmaceutical Industries Ltd Intravenous infusion dosage form for pemetrexed
EP3962453A4 (en) 2019-05-01 2023-01-25 Intas Pharmaceuticals Ltd. STABLE, READY-TO-USE AQUEOUS PHARMACEUTICAL COMPOSITION OF PEMETREXED

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
CA2361929C (en) 1999-03-16 2009-05-26 Kao Corporation Liquid deodorant
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
US9655898B2 (en) 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법

Also Published As

Publication number Publication date
US20150073000A1 (en) 2015-03-12
WO2013144814A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
IN2012DE00912A (enExample)
MY172578A (en) Oral dosing of glp-1 compounds
IN2014DN10670A (enExample)
MX2015010971A (es) Derivado novedoso de pirazol.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MY163083A (en) Solid forms of a pharmaceutically active substance
IN2014DN10386A (enExample)
MX2022011225A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
MX362879B (es) Usos novedosos.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
IN2014MN02236A (enExample)
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
PH12015501386A1 (en) Tricyclic compounds
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IN2013MU03641A (enExample)
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
EP3132797A4 (en) Use of composition containing iron (ii) amino acid chelate in preparation of drug for ameliorating diabetes
MY195384A (en) Two-Component Composition
MX2013012918A (es) Formulaciones de liberacion sostenida de paracetamol.
PH12015502706A1 (en) Oral formulation for the treatment of cardiovascular diseases